Diabetic Retinopathy News and Research RSS Feed - Diabetic Retinopathy News and Research

In the initial stages, people with diabetic retinopathy may not notice their vision changing. Diabetics sometimes experience rapid changes in blood sugar that can temporarily cause blurry vision even when retinopathy is not present. If a person notices a few specks or spots floating in his visual field, this may mean he has developed proliferative diabetic retinopathy, the growth of abnormal new blood vessels on the retina and optic nerve. High blood sugar levels have been linked in studies to retinal blood vessel abnormalities. Blurred vision may occur when the macula--the small area at the center of the retina--swells as it fills with fluid that has leaked from retinal blood vessels. Because damage to the eye often develops slowly, early detection of diabetes and control of blood sugar through diet and medications can make a crucial difference in saving vision.

Effective diabetic retinopathy treatments include laser photocoagulation for early to moderate stages and a microsurgery called vitrectomy for repair of eyes with extensive damage. Injectable and oral medications that act on abnormal blood vessels to control diabetic retinopathy before vision loss occurs are now in development. Early detection would be key to the effectiveness of these treatments, also.
First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for diabetic eye disease, today announces that the first patient has been enrolled in its Phase II CIRCLE study evaluating the efficacy and safety of multiple doses of ocriplasmin in inducing total posterior vitreous detachment (PVD) in patients with non-proliferative diabetic retinopathy (NPDR). [More]
New study reveals better treatment options for proliferative diabetic retinopathy

New study reveals better treatment options for proliferative diabetic retinopathy

This National Diabetes Month, there is some good news for people with eye complications from diabetes. Earlier this month, a network of researchers supported by the National Eye Institute (NEI) found that the drug Lucentis (ranibizumab) can be highly effective for treating proliferative diabetic retinopathy, an eye disease that can occur as a complication of diabetes. [More]
Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

In a randomized clinical trial of more than 300 participants, researchers from Johns Hopkins and elsewhere have found that ranibizumab — a drug most commonly used to treat retinal swelling in people with diabetes — is an effective alternative to laser therapy for treating the most severe, potentially blinding form of diabetic retinal disease. Results of the government-sponsored study also show that the drug therapy carries fewer side effects than the currently used laser treatment. [More]
Tyrogenex announces results from phase 1 study of orally-administered X-82 in patients with AMD

Tyrogenex announces results from phase 1 study of orally-administered X-82 in patients with AMD

Tyrogenex, a privately held company focused on the development of targeted therapeutics for cancer and ophthalmology, today announced data from its phase 1 open-label study of orally-administered X-82 in patients for wet age-related macular degeneration (AMD). [More]
Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Among patients with proliferative diabetic retinopathy, treatment with an injection in the eye of the drug ranibizumab resulted in visual acuity that was not worse than panretinal photocoagulation at 2 years, according to a study appearing in JAMA. [More]
RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

RXi Pharmaceuticals Corporation a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced the initiation of a Phase 1/2 clinical trial in ophthalmology. The clinical study RXI-109-1501 will evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases. [More]
Discovery offers promising alternative to current therapies for AMD and ROP

Discovery offers promising alternative to current therapies for AMD and ROP

A research team led by scientists at Beth Israel Deaconess Medical Center and the University of New Mexico School of Medicine has identified a small molecule that treats animal models of aged macular degeneration (AMD) and retinopathy of prematurity (ROP) by preventing the overgrowth of blood vessels that are characteristic of these two retinal diseases. [More]
Saint Louis University ophthalmologist offers tips to manage night vision issues

Saint Louis University ophthalmologist offers tips to manage night vision issues

Owls and cats are at an advantage as the days get darker, but humans may notice their vision takes a hit during their evening commute home as daylight hours shrink. [More]
Warwick researchers win prestigious RCGP award for work on diabetes

Warwick researchers win prestigious RCGP award for work on diabetes

Researchers from the University of Warwick have won a prestigious award for their work on diabetes. The paper, entitled Influence of primary care practices on patients' uptake of diabetic retinopathy screening: a qualitative case study, was named Research Paper of the Year in the diabetes category, by the Royal College of General Practitioners (RCGP). [More]
Latinos with African ancestry at higher risk for glaucoma

Latinos with African ancestry at higher risk for glaucoma

Latinos with African ancestry are at a higher risk for high pressure within the eye, a condition that if untreated can damage the optic nerve and impair vision, according to a report in the journal Ophthalmology. [More]
Kaiser Permanente recognizes three projects for advancing quality and patient safety to transform care

Kaiser Permanente recognizes three projects for advancing quality and patient safety to transform care

As part of Kaiser Permanente's culture of continuous improvement, the organization annually recognizes outstanding projects across the nation's largest integrated health system that advance quality and patient safety. Recently, three winners were honored for their efforts in supporting patient care through technology, advanced sepsis intervention and improving early detection of diabetic retinopathy. [More]
Diabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of Polyphotonix

Diabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of Polyphotonix

In the UK there are currently over 3.5 million people who have diabetes, with a growth rate exceeding 280,000 people per year. Diabetic retinopathy is the most common complication of diabetes. [More]
Lack of patient understanding of the true cost of medication non-adherence

Lack of patient understanding of the true cost of medication non-adherence

A new report released today, Friday 16th October, by Omnicell, throws the spotlight on the ‘missing millions’ in the NHS and the staggering cost to the nation of medication non-adherence. [More]
Novel ligand peptide-mimic inhibits abnormal overgrowth of blood vessels, may lead to new anti-cancer drugs

Novel ligand peptide-mimic inhibits abnormal overgrowth of blood vessels, may lead to new anti-cancer drugs

An international research team led by scientists at the University of New Mexico Cancer Center discovered and developed a novel ligand peptide-mimic that inhibits abnormal overgrowth of blood vessels in retinal diseases and tumors. The discovery could lead to new drugs that keep cancers from growing. The team published a paper in the journal Science Translational Medicine. [More]
ILUVIEN continues to show positive results in Europe

ILUVIEN continues to show positive results in Europe

Alimera Sciences Limited, the European subsidiary of Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced the availability of real world data from 28 injections of ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) in Europe, presented in a review paper authored by Fahd Quhill, Consultant Ophthalmologist, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, South Yorkshire, U.K. [More]

Alimera Sciences announces results from ongoing study on ILUVIEN

Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that Alimera Sciences Limited, its European subsidiary based in London, revealed interim six-month data on ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) from the ongoing study referred to as RESPOND, a non-Randomised, open-label, multicenter phase 4 pilot study on the Effect and Safety of ILUVIEN Fluocinolone Acetonide in chronic diabetic macular edema Patients cOnsidered iNsufficiently responsive to available therapies with or without intravitreal corticosteroiD therapy. [More]
Annual diabetic retinopathy screening for children with type 1 diabetes should begin at later age, study says

Annual diabetic retinopathy screening for children with type 1 diabetes should begin at later age, study says

A new study has found that the occurrence of advanced forms of a diabetic eye disease remains low among children living with diabetes, regardless of how long they have had the disease or their ability to keep blood sugar levels controlled. Researchers are therefore recommending that most children with type 1 diabetes delay annual diabetic retinopathy screenings until age 15, or 5 years after their diabetes diagnosis, whichever occurs later. [More]
Research with UWF imaging may change how diabetic eye disease is assessed and treated

Research with UWF imaging may change how diabetic eye disease is assessed and treated

For decades, clinicians have detected and monitored diabetic eye disease with standard retinal photographs that cover about a third of the retina. In recent years, an emerging class of ultrawide field (UWF) cameras has given a substantially larger view of the retina, providing new insight on the presentation and natural history of retinal disease. [More]
Transplanting mesenchymal stromal cells derived from amniotic membranes can benefit eye diseases

Transplanting mesenchymal stromal cells derived from amniotic membranes can benefit eye diseases

A team of researchers in South Korea has successfully transplanted mesenchymal stromal cells (MSCs) derived from human amniotic membranes of the placenta (AMSCs) into laboratory mice modeled with oxygen-induced retinopathy (a murine model used to mimic eye disease). [More]
Sigma 1 receptor appears to play vital role in supporting the retina

Sigma 1 receptor appears to play vital role in supporting the retina

A receptor that is already a target for treating neurodegenerative disease also appears to play a key role in supporting the retina, scientists report. [More]
Advertisement
Advertisement